K
Kevin S. Berman
Researcher at University of Texas Southwestern Medical Center
Publications - 6
Citations - 4387
Kevin S. Berman is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: MAP kinase kinase kinase & ASK1. The author has an hindex of 6, co-authored 6 publications receiving 4182 citations.
Papers
More filters
Journal ArticleDOI
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.
Gray W. Pearson,Fred L. Robinson,Tara Beers Gibson,Bing E. Xu,Mahesh Karandikar,Kevin S. Berman,Melanie H. Cobb +6 more
TL;DR: Nonenzymatic mechanisms that impact MAP kinase functions and findings from gene disruption studies are highlighted and particular emphasis is on ERK1/2.
Journal ArticleDOI
Isolation of TAO1, a Protein Kinase That Activates MEKs in Stress-activated Protein Kinase Cascades *
TL;DR: The activation of and binding to MEK3 by TAO1 implicates TAO2 in the regulation of the p38-containing stress-responsive MAP kinase pathway, and showsTAO1 is highly expressed in brain, as is a homolog TAO 2.
Journal ArticleDOI
Isolation and characterization of pmk-(1-3): three p38 homologs in Caenorhabditis elegans.
TL;DR: PMK-1 and PMK-2 phosphorylated activating transcription factor-2 (ATF-2), indicating an activity similar to mammalian p38, and the promoter of the pmks is active throughout the intestine.
Journal Article
Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB
Kevin S. Berman,Udit Verma,Gwyndolen Harburg,John D. Minna,Melanie H. Cobb,Richard B. Gaynor +5 more
TL;DR: It is demonstrated that treatment of the non-small cell lung carcinoma cells NCI-H157 and NCi-H1299 with sulindac greatly enhances TNF-α-mediated apoptosis, and it is suggested that sulindAC and other nonsteroidal anti-inflammatory drug inhibitors of NF-κB activation may serve as useful agents in cancer chemotherapy.